			0
$\rightarrow 0$	→ https://web.archive.org/web/20170403170533/http:/drugsdb.eu/drug.php?d	d=L-cystein Ш☆ 1	<i>V</i> ~
et archive h	tp://drugsdb.eu/drug.php?d=L-cysteine%20Hydrochloride&m=Sandoz%20Inc&id=083366d6-0437-4ee0-90d4-440a	a5b5d03b5.x Go AUG APR MAY	E
UNIIIOUIIIIIO 2 c 24 /	aptures ug 2018 - 3 Apr 2017	2016 2017 2018	▼ Ab
	www.drug	gsDB.eu	
	DUCC Data Das	With permis	sion of
	nuus Daladas	of Me	dicino
You are here: H	Iome > Prescription(RX) Drugs > L > L-cysteine Hydrochloride (Sandoz Inc)	Loading	
		Prescription Marketed Drugs Alpha AI BI CI DI EI FI GI HI II JI KI LI MI NI	betically
Name:	L-cysteine Hydrochloride	S T U V W X Y Z 0-9	
Manufacturer:	Sandoz Inc	Categories:	
Category:	Prescription Marketed Drugs	Prescription(RX) Drugs	
		Homeopathic Drugs	
		Animal Drugs	
		Feedback	
	hydrochloride injection, solution		
	Sandoz Inc Disclaimer: This drug has not been found by FDA to be safe and		
	effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.		
	Hydrochloride Injection, USP		
		-	
	PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION		
DESCRIPTION			
L-Cysteine Hydr	ochloride Injection, USP, 50 mg/mL, is a sterile, nonpyrogenic solution. Each mL		
replaced with Ni	trogen. pH 1.02.5		
is relatively unst	able over time, eventually converting to insoluble cystine. To avoid such precipitation,	:	
L-Cysteine Hydr Acid Injections i	ochloride Injection USP is intended to be used as an additive with crystalline Amino nmediately prior to administration to the patient.		
The structural fo	rmula of Cysteine Hydrochloride Monohydrate USP is:		
HSCH ₂ – C	– C00H•HCI•H ₂ 0		
1			
NH	2		

-	\rightarrow	0	ŵ	A	https:	//web.a	archive.	.org/v	veb/20	017040	31705	33/ht	tp:/di	rugsdb	.eu/dr	ug.php	?d=L-c	ystein	D	☆	չե	2	G
						24-1	4-1- 47 -					01- 01		00.00	,		40-515	001.0			MAY	~~	
UayBa	ckMachi	10 2 0 24	captures	db.eu/d 3H7NG Apr 2017	rug.php	?d=L-cys	teine%20	OHydra	chloride	s&m=Sa	ndoz%2	UInc&R	d=0833	58888-04	137-4ee()-90d4-4	40a5b5d	0365.x	2	00 016	2018	Ē	iout thi
	CLINIC L-Cyste infants conside	AL PHA eine is sy lack the ered to b	RMAC Inthesiz enzyme e an es	DLOG ed from enece sential	i Y m met ssary I amin	hionine to effe o acid	e via th ct this in infar	ne tra conve nts.	ns-su ersion	lfuratio . Ther	on patl efore,	iway L-Cy	in the stein	e adul e is ge	t, but n enerally	ewbor /	n						
	INDICA L-Cyste Crystall receivir	TIONS eine Hyd line Amii ng total p	AND US rochlori no Acid parenter	SAGE de Inje Injecti al nutr	ection, ions to rition.	USP in meet	s inten the intr	ided f raven	or use Ious a	e only imino a	after o acid n	lilutio utritio	n as a nal re	an ado equire	ditive to ments	o of infa	nts						
	CONTR This pre impaire	RAINDIC eparation ed nitroge	ATION n should en utiliza	S 1 not b ation.	e use	d in pa	tients \	with h	iepati	c com	a or m	etabo	olic di	sorde	rs invo	lving							
	WARN Periphe especia perform continu protein Adminis acid im Adminis increas Solution heart fa	INGS eral intra ally in pa hed perio e to rise intake. stration o balances stration o ing BUN ns conta ailure, se	venous tients w odically a . It shou of amino s, metato f amino l, as doe ining so vere rei	infusio ith imp and in ild be i colic al colic a	on of a baired fusion noted solutio solutio prote ion sh sufficie	imino a hepati discor that a i ons to a is, prer ons in t in dieta ould be ncy, ai	acids m c or rei ntinued modes a patiel renal az he pre- ary con e used nd in cl	nay ir nal fu if BU st rise nt wit zoten sence with linica	nduce inction JN lev in BU h hep nia, hy e of in ent. great I state	a rise n. App vels ex JN nor vatic in vperar npaire care, i es in w	in blo ropria ceed i mally sufficie nmone d rena f at all hich th	od un te lab norma occur ency emia, I func I, in p nere e	ea nit orato al pos rs as may r stupo ction r atient exists	trogen ory tes stpran a result or and may a ts with edem	(BUN ts shou dial lim in seru coma ugmen conge a with) uld be iits and crease im ami t an estive sodiui	i d no n						
	retention Solution hyperka Solution respirat is an in Hypera it is ess Instanc dysfund and imi	on. ns which alemia, s ns conta tory alka creased mmoner cential th es of as ction. Th mature o	i contair severe re losis. Ad level or nia is of at blood ymptom e mecha or subcli	i potas enal fa etate i cetate an im speci l amm atic hy anism:	ssium ailure a ion sh shoul paireo al sign onia le yperan s of th r impa	ion sho and in o ould be d be ao 1 utiliza nificano evels b mmone is reac ired live	condition condition diminist ation of ce in in ive mease mia has tion an er func	e use ons in with tered f this fants sured ave b e not ction.	d with great with g ion su , as it freque clear	great ch pota care in great c ich as can re uently eported ly defin	care, assium patie are in seven sult ir sult in in infa d in pa ned bu	if at a reternts w those hep men nts. atients at may	all, in ntion vith m e con patic in tal re s with y invo	patien is pre hetabo ditions nsuffic tardat hout ov blve ge	ts with sent. lic or s in wh tiency. ion. Th vert live enetic (ich the nerefor er defects	ere e						
	Freque Monito electrol osmola Urinary Safe us underta the phy	ent Clini ring Du ytes, am rity and osmola se during aken duri rsician.	cal Eva ring Ad imonia, hemogr rity and pregna ing preg	luation minis choles am. W glucos incy ha incy ha	n and tratio sterol, /hite b se sho as not / only	Labor n. Bloc acid-b lood co uld be been o when t	atory d stud ase ba bunt ar detern establis his is c	Dete lies sl alance nd blo mined shed, deem	rmina hould e, serr bod cu l frequ , there ed es	ations includ um pro iltures uently. efore, i sential	are N e gluc teins, are to nfusio to the	eces ose, kidne be d n of a patie	sary urea ey an letern amino ents'	for Pr nitroge d liver nined i acids welfar	oper en, ser function findica shoul e, as ju	um on test ated. d be udged	s, by						
	WARN prolong at risk l solutior Resear receive associa rates oi	ING: Thi ped paren because ns, which rch indica parente ated with f adminis	IS produ nteral a their kio contail ates tha ral level central stration	ct con dminis dneys n alum t patie ls of ai nervo	tains a tration are im inum. nts wi luminu us sy:	aluminu n if kidn nmature th impa im at g stem ai	Jm tha Tey fun e, and aired ki greater nd bon	nt may inction they idney than ne tox	/ be to is imp requin funct 4 to 5 icity.	oxic. A paired re large tion, in 5 mcg/ Tissue	Iumini Pren e amo cludin kg/day loadii	um m hature unts (g pre accu ng ma	ay re- e neoi of cal matu umula ay occ	ach to nates Icium a re neo ate alu cur at	xic lev are pa and ph onates, minum even le	els wit rticulai ospha who n at lev ower	n rly te rels						

Inter-lifering Inter-lifering Control Control Inter-lifering Control Contro Contro Contro
PRECAUTIONS Special care must be taken when administering hypertonic glucose to provide calories in diabetic or prediabetic patients. Because of its antianabolic activity, concurrent administration of tetracycline may reduce the nitrogen sparing effects of infused amino acids. Do not withdraw venous blood for blood chemistries through the peripheral infusion site, as interference with estimations of nitrogen containing substances may occur. Intravenous feeding regimens which include amino acids should be used with caution in patients with a history of renal disease, pulmonary disease, or with cardiac insufficiency so as to avoid excessive fluid accumulation. The effect of infusion of amino acids, without dextrose, upon carbohydrate metabolism of children is not kine time.
Nitrogen intake should be carefully monitored in patients with impaired renal function. For long-term total nutrition, or if a patient has inadequate fat stores, it is essential to provide adequate exogenous calories concurrently with the amino acids. Concentrated dextrose solutions are an effective source of such calories. Such strongly hypertonic nutrient solutions should be administered through an indwelling intravenous catheter with the tip located in the superior vena cava. ADVERSE REACTONS Local reactions consisting of a warm sensation, erythema, phiebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids, particularly if the other substances, such as antibiotics, are also administered through the same site. In such cases the infusion site should be changed promptly to another vein. Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous imitation. Electrolyte additives should be spread throughout the day. Irritating additive medications may need to be injected at another venous site. Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions. Drug Abuse and Dependence None known. Costance And DoministreATON Crysteline Hydrochloride Injection USP is intended for use only after dilution in Crystalline Amino Acid injection. The admixture is then diluted with 250 mu of dextrose 50% or such lesser volume as indicated. Equal volumes of 5% Crystalline Amino Acid Injection and dextrose 50% or such lesser volume as found to contain cyclatiline Amino Acid Injection 25% in dextrose 50% produce a final solution within oxid injection 25% in dextrose 50% produce a final solution within contains crystalline Amino Acid Injection 25% Crystalline Amino Acid Injection 25% Crystalline Amino Acid Injection 25% produce a final solution within contains crystalline Amino Acid Injection 25% Crystalline Amino Acid Injection 25% Crystalline Amino Acid Inje

E L-CYSTEINE HYD	DROCHL × +	\sim						_		×
$ ightarrow$ O $rac{1}{2}$	A https://web.a	rchive.org/web/20	170403170533/ht	tp:/drugsdb.eu,	/drug.php?d=L·	cystein 🛄	☆ ☆	= <i>D</i> _	È	
INTERNET ARCHIVE SEATING S	sdb.eu/drug.php?d=L-cys be red Apr2017:	teine%20Hydrochloride	&m=Sandoz%20Inc&id	=083366d8-0437-4	lee0-90d4-440a5b5	603b5.x Go	AUG APR MAY	E	O	⊗ ⊻ pbure
entries increase the po The withdrawal of con However, should this	ainer contents shou tot be possible, a m	and particulate co uld be accomplishe aximum time of 4	ntamination. ed without delay hours from initial	using aseptic t closure entry	echnique. is permitted					
to complete fluid trans	fer operations.								н	
RECOMMENDED STO Keep under laminar flo within 4 hours after ini	DRAGE CONDITIO w hood at room ten ial entry.	NS AFTER OPEN nperature. Any un	IING used portion of th	ne vial must be	discarded				н	
HOW SUPPLIED									н	
L-Cysteine Hydrochlor	ide Injection, USP (50 mg/mL) is supp	plied as follows:							
PACKAGE NDC Number Volum										
66758-005-01 50 mL 66758-005-02 5 × 50	mL									
Also available as:	 									
NDC Number Volu	AL ne									
66758-004-01 10 m 66758-004-02 10 ×	L 10 mL									
Store at controlled roo For Sandoz Inc. Custo	m temperature 15°- mer Service, call 1-	30°C (59°-86°F) E -800-525-8747	o not freeze.							
Rx only Manufactured for:										
SANDOZ										
Revised: November 20	009									
L-028-00										
Package Label - Prin	cipal Display Pane	l - 50 mL Vial								
SANDOZ Rx only NDC 66	758-005-01									
L-Cysteine										
PHARMACY BULK P										
NOT FOR DIRECT IN 50 mg/mL	FUSION									
For IV Use Only After	Dilution									
50 mL	A OM									
L-018-00 PHARMACY BULK P	ACKAGE									

NET ARCHIVE Intep.//drugsdo.ed	u/drug.php?d=L-cyste	eine%20Hydrochloride	e&m=Sandoz%20Inc&id=0	83366d6-0437-4ee0)-90d4-440a5t	o5d03b5.x	00	APR MAY	
2 captures							2018	03	About
24 Aug 2016 - 3 Apr 201							2010	2018	About t
	Each mL contains	: 50 mg L-Cysteine Hvd	Irochlatide	7					
S SANDOZ	Monohydrate, US replaced with Nitr	P; Water for Injection, U rogen: pH 1.3-2.5	USP, q.s.; Air						
L-Cysteine	Directions for Use Warning: For IV s	e: See package insert.	ed before use.						
Hydrachlaride Injection, USP	Contents should b	be dispensed promptly a	after initial closure						
NOT FOR DIRECT INFUSION	Store at controlle	d room temperature							
50 mg/mL	Contains no more	Than 5,000 mcg/L of al	luminum.						
Do Not Dispense As A Unit	Manufactured for:	 Sandoz Inc. Princeton, NJ 08540 							
L-018-00 BUYUS AND	Date/Time Entered	INTERCENTION INTERCENCE	11111291						
Package Label - Principal	l Display Panel	- 50 mL Vial Ca	arton						
SANDOZ									
5 × 50 mL Vials NI L-Cysteine Hydrochloride	DC 66758-005-0	J2							
Injection, USP	•								
50 mg/mL									
Pharmacy Bulk Package									
For IV Use Only After Diluti	ion								
Rx only									
5 x 50 mL Vials	A SA	NDOZ	DC 66758-005-02						
L-Cystein	e Hydrochlo	ride							
L-Cystein Injection, US	e Hydrochlo P	ride							
L-Cystein Injection, US 50 mg/m	ie Hydrochlo ^{se} L	ride							
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa Not For Direct Int	ie Hydrochlo ^{SP} iL ackage ^{Vision}	ride	Br only						
L-Cystein Injection, US 50 mg/m Permey Dak P Not For Direct Int For IV Use Only 2	ne Hydrochlo SP L ackage Vision After Dilution	ride	Rx only						
L-Cystein Injection, US 50 mg/m Pharmay Bak Pa Not For Direct Int For IV Use Only A	ne Hydrochlo P L ackage Union Witer Dilution	ride	Rx only						
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pe Not For Direct Inf For IV Use Only J	Hydrochlo P L actage Withon Nher Dilution HLORIDE	ride	Rx only						
L-Cystein Injection, US 50 mg/m Pharmacy Bilk PE Not For Direct Inf For IV Use Only A	Hydrochlo P L actage usion wher Dilution HLORIDE ion, solution	ride	Rx only						
L-Cystein Injection, US 50 mg/m Pharmacy Buk Pc Not For Direct Inf For IV Use Only A L-CYSTEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Information	HLORIDE		Rx only	NDC	36758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Buk P Not For Direct Inf For IV Use Only A L-CYSTEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Type Route of Administration	He Hydrochlo P L adage Wice Wher Dilution HLORIDE ion, solution HUMAN PRESC INTRAVENOUS	ride RIPTION DRUG	Rx only Item Code (Source) DEA Schedule	NDC:	36758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Buk P Not For Direct Inf For IV Use Only A L-CYSTEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Mane	He Hydrochlo P L adage Wice Wher Dilution HLORIDE ion, solution HUMAN PRESC INTRAVENOUS loiety	ride RIPTION DRUG	Rx only Item Code (Source) DEA Schedule Stranoth	NDC:	36758-005				
L-Cystein Injection, US 50 mg/m Pharmey Buk P Not For Direct Inf For IV Use Only A L-CYSTEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYST	HUDRIDE in, solution HLORIDE ion, solution HUMAN PRESC INTRAVENOUS loiety TEINE)	ride RIPTION DRUG Basis of CYSTEINE	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE	NDC: Strength 50 mg in 1	36758-005 1 mL				
L-Cystein Injection, US 50 mg/m Pharmay Buk R Not For Direct Inf For IV Use Only A L-CY STEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CY STEINE HYDROCHLORIDE (CYS' Inactive Ingredients Ingredient Name	HUDRIDE intravenous intraveno	RIPTION DRUG Basis of CYSTEINE	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Strength	NDC: Strength 50 mg in 1	96758-005 1 mL				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not for Direct thin You for Direct thin You for Direct thin You for Direct thin You for Administration Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYPROCHLORIDE (CYST Inactive Ingredients Ingredient Name WATER	He Hydrochlo P L actage Witch Wher Dilution HLORIDE ion, solution HUMAN PRESC INTRAVENOUS loiety TEINE)	RIPTION DRUG Basis of 1 CYSTEINE	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Strength	NDC: Strength 50 mg in 1	36758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not for Direct thin For IV Use Only / L-Cysteine hydrochloride injecti Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CystEine HydrochLORIDE (CYST Inactive Ingredients Ingredient Name WATER Product Characteristics	He Hydrochlo P L acage Wice Wher Dilution HLORIDE ion, solution HUMAN PRESC INTRAVENOUS loiety TEINE)	RIPTION DRUG Basis of 1 CYSTEINE	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Strength	NDC: Strength 50 mg in 1	36758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not for Direct till Product Information Product Information Product Information Active Ingredient/Active M Ingredient Name Cysterise Hyprocol. Loride (CYST Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape	A Hydrochlo P L Actage Wer Dilution HLORIDE ion, solution HUMAN PRESC INTRAVENOUS IOIEty TEINE)	ride RIPTION DRUG Basis of 1 CYSTEINE Score Size	Rx only Item Code (Source) DEA Sohedule Strength HYDROCHLORIDE Strength	NDC:1	98758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Paramacy Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYST Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains	All Hydrochio P. L actage Usion HLORIDE Ion, solution HUMAN PRESC INTRAVENOUS Ioiety TEINE)	RIPTION DRUG Basis of CYSTEINE Score Size Imprint Code	Rx only Item Code (Source) DEA Schedule Strength Strength Strength	NDC: Strength 50 mg in 1	36758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not For Direct time For IV Use Only 2 L-CY STEINE HYDROCC I-cysteine hydrochloride inject Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CY STEINE HYDROCHLORIDE (CYST Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging	A Hydrochio P L actage Usion HLORIDE Ion, solution HUMAN PRESC INTRAVENOUS Ioiety TEINE)	ride RIPTION DRUG Basis of CYSTEINE Score Size Imprint Code	Rx only Item Code (Source) DEA Schedule Strength Strength Strength	NDC:1	36758-005				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa Not For Direct the Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYS' Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #them Code Package Desc	e Hydrochio P L actage Usion HLORIDE Ion, solution HUMAN PRESC INTRAVENOUS INTRAVENOUS Ioiety TEINE)	ride RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code (VIAL) in 1	Rx only Item Code (Source) DEA Schedule Strength HyDROCHLORIDE Strength Utilievel Packaging Contains a V(A) EHAPMARY	NDC:1 Strength 50 mg in 1	36758-005				
L-Cystein Injection, US 50 mg/m Paramey Buk Pa Not For Direct the Not For Direct the Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYS Inactive IngredientS Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #tem Code Packaging #tem Code NDC:09758-005 5 SyNa, PAckage Desc 1NDC:09758-005 5 SyNa, PAckage Desc	e Hydrochio P L actage Usion HLORIDE Ion, solution HUMAN PRESC INTRAVENOUS INTRAVENOUS Ioiety TEINE)	ride RIPTION DRUG Basis of I CYSTEINE Score Size Imprint Code (VIAL) in 1	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Strength Unutilievel Packaging contains a VIAL, PHARMACY 21)	NDC: Strength 50 mg in 1 BULK PACKAGE (6	36758-005				
L-Cystein Injection, US 50 mg/m Paramacy Bulk Pa- Not For Direct the Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYS Inactive Ingredient/Active M Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Package Desc INDC:00758-005- 5 VIAL, PHARM 02 CARTON INDC:00758-005- 5 Or Lin 1 VIAL, 01	IL ACARGE VIEW OF A CONTRACT OF A CONTRACT.	ride RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code (VIAL) in 1 CACKAGE T	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Strength Multilevel Packaging contains a VIAL, PHARMACY 1) This package is contained wit	NDC: Strength 50 mg in 1 BULK PACKAGE (6	36758-005 1 mL 16758-005- 758-005-02)				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not For Direct the Product Part Pharmacy Bulk Pa- Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYS Inactive Ingredient/Active M Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Packaging #Item Code NDD-68758-005- 5 VIAL PHARM 02 CARTON NDC-68758-005- 5 VIAL PHARM	te Hydrochio P L actage Usion HLORIDE Ion, solution HUMAN PRESC INTRAVENOUS INTRAVENOUS Ioiety TEINE) Sciption ACY BULK PACKAGE PHARMACY BULK PA	ride RIPTION DRUG Basis of CYSTEINE Score Size Imprint Code I(VIAL) in 1 c ACKAGE T	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Strength Multilevel Packaging contains a VIAL, PHARMACY 1) This package is contained wit	NDC: Strength 50 mg in 1 BULK PACKAGE (6 hin the CARTON (66	36758-005 1 mL 16758-005- 758-005-02)				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk F2 Not For Direct the Product Information Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORIDE (CYS Inactive Ingredients Ingredient Name CYSTEINE HYDROCHLORIDE (CYS Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Packaging #Item Code NDLC60758-005- 5 VIAL PHARW 02 CARTON INDLC60758-005- 5 OmL in 1 VIAL 01 Marketing Information	IL Addage Sector Control of Se	RIPTION DRUG RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code (VIAL) in 1 C ACKAGE T Score CYSTEINE	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Multilevel Packaging contains a VIAL, PHARMACY 1) This package is contained wit Marketing Start Data	NDC:1 Strength 50 mg in 1 BULK PACKAGE (6 hin the CARTON (68	26758-005 1 mL 16758-005- 758-005-02)				
L-Cystein Injection, US 50 mg/m Pharmacy Buk F2 Not For Direct the Product Direct the Injection Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORDE (CYS Inactive Ingredients Ingredient Name CYSTEINE HYDROCHLORDE (CYS Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Packaging #Item Code NDC:68758-005 5 VIAL PHARW 02 CARTON INDC:68758-005 50 mL in 1 VIAL 01 Marketing Information Marketing Category Napproved drug other	e Hydrochio P L actage Widon HLORIDE Ion, solution HUMAN PRESC INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS PHARMACY BULK PACKAGE PHARMACY BULK PACKAGE PHARMACY BULK PACKAGE	RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Multilevel Packaging contains a VIAL, PHARMACY 1) This package is contained wit Marketing Start Date (12/01/2008	BULK PACKAGE (6 hin the CARTON (66 e Marketing Er	96758-005 1 mL 16758-005- 758-005-02) nd Date				
L-Cystein Injection, US 50 mg/m Pharmacy Buk Pa Not For Direct the Product Direct the Injection Product Type Route of Administration Active Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORDE (CYS Inactive Ingredient/Active M Ingredient Name CYSTEINE HYDROCHLORDE (CYS Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Packaging #Item Code Data Carbon SomLin 1 VIAL 01 Marketing Information Marketing Category Application	e Hydrochio P L actage Widon Mher Dilution HUORIDE Ion, solution HUMAN PRESC INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS PHARMACY BULK PACKAGE PHARMACY BULK PACKAGE PHARMACY BULK PACKAGE PHARMACY BULK PACKAGE	RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Multilevel Packaging contains a VIAL, PHARMACY 10 This package is contained wit Marketing Start Date 12/01/2008	BULK PACKAGE (6 inin the CARTON (66 e Marketing Et	36758-005 I mL 16758-005- 758-005-02)				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not for Direct thin Year V Use Only 2 L-CY STEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Information Active Ingredient/Active M Ingredient Name Cysteine HyDROCHLORIDE (CYS' Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Package Deso Flavor Contains Packaging #Item Code Package Deso 1NDC-00758-005- 5 VIAL, PHARIM 02 CARTON 1NDC-00758-005- 5 VIAL, PHARIM 03 CARTON 1NDC-00758-005- 5 VIAL, PHARIM 04 CARTON 1NDC-00758-005- 5 VIAL, PHARIM 05 CARTON 1NDC-00758-005- 5 VIAL, PHARIM 1NDC-00758-005- 5 VIAL	IE Hydrochio	RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code (VIAL) in 1 C ACKAGE T bgraph Citation	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Multilevel Packaging contains a VIAL, PHARMACY 11) This package is contained wit Marketing Start Date 112/01/2008	BULK PACKAGE (6 hin the CARTON (60 e Marketing Ei	36758-005 I mL 16758-005- 758-005-02)				
L-Cystein Injection, US 50 mg/m Pharmacy Bulk Pa- Not for Direct time For V Use Only 2 L-CY STEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Information Active Ingredient/Active M Ingredient Name Cystenke HyDROCHLORIDE (CYS' Inactive Ingredient/Active M Ingredient Name VATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Package Struct Distribution Distribution Distribution Distribution Distribution Marketing Information Marketing Category Dispression Distribution Di	IL ACAGE Second Second	ride RIPTION DRUG Basis of 3 CYSTEINE Score Size Imprint Code (VIAL) in 1 C ACKAGE T Agraph Citation	Rx only Item Code (Source) DEA Schedule Strength HYDROCHLORIDE Ontains a VIAL, PHARMACY I) This package is contained wit Marketing Start Date 12/01/2008	NDC:1 Strength 50 mg in 1 BULK PACKAGE (6 hin the CARTON (66 e Marketing El	28758-005 I mL 18758-005- 758-005-02) nd Date Sandoz Inc				
L-Cystein Injection, US 50 mg/m Pharmacy Bilk Pa- Not for Direct till Product Information Product Information Product Information Active Ingredient/Active M Ingredient Name Cystenke HypRoCHLORIDE (CYST Inactive Ingredient/Active M Ingredient Name Cystenke HypRoCHLORIDE (CYST Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Package Desc INDC:60758-005 5 VIAL PHARM6 02 CARTON 1NDC:60758-005 5 VIAL PHARM6 02 CARTON 100 CARTON Applicatio Unapproved drug other	IL ACAGE SALARS AND	ride RIPTION DRUG Basis of 1 CYSTEINE Score Size Imprint Code I(VIAL) in 1 CACKAGE T Sgraph Citation	Rx only Item Code (Source) DEA Sohedule Strength HYDROCHLORIDE Strength Ontains a VIAL, PHARMACY I) This package is contained wit Marketing Start Date 12/01/2008	BULK PACKAGE (6 hin the CARTON (68 e Marketing Ei	20758-005 I mL 10758-005- 758-005-02) nd Date Sandoz Inc				
L-Cystein Injection, US 50 mg/m Pharmacy Bilk Pa- Not For Direct time For IV Use Only / L-CY STEINE HYDROCI I-cysteine hydrochloride injecti Product Information Product Information Product Information Active Ingredient/Active M Ingredient Name Cysterike HYDROCHLORIDE (CYS' Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Package Desc Flavor Contains Packaging #Item Code Package Desc Flavor Contains Packaging #Item Code Package Desc Contains Packaging #Item Code Package Desc Contains Package Desc Contains Packaging #Item Code Package Desc Contains Packaging #Item Code Package Desc Contains Packaging #Item Code Package Desc Contains Packaging #Item Code Package Desc Contains Packaging #Item Code Package Desc Contains Package De	IL Hydrochio	ride RIPTION DRUG Basis of CYSTEINE Score Size Imprint Code (VIAL) in 1 c ACKAGE T Opraph Citation	Rx only Item Code (Source) DEA Schedule Strength Characteristic Strength Strength Utilievel Packaging Contains a VIAL, PHARMACY D) This package is contained wit Marketing Start Date (12/01/2008	BULK PACKAGE (6 hin the CARTON (60 e Marketing Er	30758-005 1 mL 10758-005- 758-005-02) nd Date Sandoz Inc				
L-Cystein Injection, US 50 mg/m Pharmacy Bilk P Not For Direct time For IV Use Only / Contains Product Information Product Information Product Information Active Ingredient/Active M Ingredient Name Cystenise HyroRoCH.Coribe (CYS' Inactive Ingredients Ingredient Name WATER Product Characteristics Color Shape Flavor Contains Packaging #Item Code Package Desc Flavor Contains Packaging #Item Code Package Desc Flavor Contains Packaging #Item Code Package Desc Flavor Contains Packaging #Item Code Package Desc Contains Packaging #Item Code Package Desc Contains Package Desc Contains Packaging #Item Code Package Desc Contains Package Desc Contain	Int.nih.gov	ride ride RIPTION DRUG Basis of CYSTEINE Score Size Imprint Code (VIAL) in 1 c ACKAGE 7 Ograph Citation hall Library of Me	Rx only Item Code (Source) DEA Schedule Strength Strength Multilevel Packaging contains a VIAL, PHARMACY 11) Marketing Start Date (12/01/2008 cdicine	BULK PACKAGE (6 hin the CARTON (60 e Marketing Er	36758-005 1 mL 16758-005- 758-005-02) nd Date Sandoz Inc				

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

